Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding

AstraZeneca300 enrolled

Overview

The purpose of this study is to determine and analyse the incidence, severity, risk factors and routine management of acute drug-induced upper gastrointestinal bleeding (UGIB) in the population of Russian patients

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Upper Gastrointestinal Bleeding

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Established diagnosis of acute upper gastrointestinal bleeding, confirmed by presence of hematemesis/ coffee ground vomiting, melena, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract * Written informed consent provided prior the start of participation in the study. Exclusion Criteria: * Subjects who are unwilling or unable to provide informed consent.

Locations (1)

Research Site

Moscow, Russia

Outcomes

Primary Outcomes

Number and percentage of patients with drug-induced upper gastrointestinal bleeding

Time frame: About 1 year

Secondary Outcomes

Number and percentage of patients with each symptom and each Forrest class of upper gastrointestinal bleeding

Time frame: About 1 year

Number and percentage of patients with concomitant diseases contributing to drug-induced upper gastrointestinal bleeding and those who receive NSAIDs, antiplatelet agents, anticoagulants, steroids or combination therapy

Time frame: About 1 year

Number and percentage of patients with each type of bleeding outcomes who received different types of hemostatic therapy

Time frame: About 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.